乌鸦传媒

Significant improvement beyond 100 weeks after single injection of mutation-agnostic MCO-010

Office procedure reduced visual field loss by 29% over 6 years versus eye drops

Drug targeting junctional zone reduces GA growth by 48% in 3 months, oral agent moderately active

Study suggests potential to eliminate a third of in-office visits without harming care

Study adds leg and ankle fractures, intracranial hemorrhage to evidence on falls, hip fracture

History of injections tied to multiple postop complications, but data open to questioning

No change in visual acuity, office-visit interval almost doubled during 6 months

Significant decrease in rate of photoreceptor loss in two randomized trials

Consistent vision effect with complement C1q inhibitor, despite no effect on lesion size

Some degree of improvement in disease status in 70% of patients treated with tarcocimab

All but one patient with nonproliferative diabetic retinopathy had stable disease or improvement

Improved visual acuity, retinal thickness at 6 and 12 weeks, but treatment burden questioned

Other studies report fewer reoperations with combo eye surgery and vision risk with shingles

Tarcocimab noninferior to aflibercept while cutting treatment burden in half